Difference between revisions of "Acute myeloid leukemia, IDH-mutated"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Line 1: Line 1:
−
<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''-->
+
{| class="wikitable" style="text-align:center; width:50%;"
−
<!--Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].-->{| class="wikitable" style="text-align:center; width:50%;"
 
 
! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Page editor'''
 
! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Page editor'''
 
|-
 
|-
Line 14: Line 13:
 
|}
 
|}
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
 +
=IDH1 relapsed or refractory, salvage therapy=
 +
==Ivosidenib monotherapy {{#subobject:214f83|Regimen=1}}==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
===Regimen {{#subobject:e548f6|Variant=1}}===
 +
{| class="wikitable" style="color:white; background-color:#404040"
 +
|<small>'''FDA-recommended dose'''</small>
 +
|-
 +
|}
 +
{| class="wikitable" style="width: 100%; text-align:center;"
 +
!Study
 +
![[Levels_of_Evidence#Evidence|Evidence]]
 +
|-
 +
|[https://www.nejm.org/doi/10.1056/NEJMoa1716984 DiNardo et al. 2018 (AG120-C-001)]
 +
| style="background-color:#91cf61" |Phase I/II
 +
|-
 +
|}
 +
====Chemotherapy====
 +
*[[Ivosidenib (Tibsovo)]] 500 mg PO once per day
 +
 +
'''Continued indefinitely'''
 +
===References===
 +
# '''AG120-C-001:''' DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL,  Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018 Jun 21;378(25):2386-2398. Epub 2018 Jun 2. [https://www.nejm.org/doi/10.1056/NEJMoa1716984 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29860938 PubMed]
  
 
=IDH2 Relapsed or refractory, salvage therapy=
 
=IDH2 Relapsed or refractory, salvage therapy=
Line 31: Line 55:
 
![[Levels_of_Evidence#Efficacy|Efficacy]]
 
![[Levels_of_Evidence#Efficacy|Efficacy]]
 
|-
 
|-
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572791/ Stein et al. 2017]
+
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572791/ Stein et al. 2017 (AG-221-C-001)]
 
| style="background-color:#91cf61" |Phase I/II
 
| style="background-color:#91cf61" |Phase I/II
 
| style="background-color:#8c96c6" |ORR: 40%
 
| style="background-color:#8c96c6" |ORR: 40%
Line 43: Line 67:
  
 
===References===
 
===References===
−
# Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Aug 10;130(6):722-731. Epub 2017 Jun 6. [http://www.bloodjournal.org/content/130/6/722.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572791/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28588020 PubMed]
+
# '''AG-221-C-001:''' Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Aug 10;130(6):722-731. Epub 2017 Jun 6. [http://www.bloodjournal.org/content/130/6/722.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572791/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28588020 PubMed]
−
=Investigational agents=
 
−
''These are drugs under study with at least some promising results for this disease.''
 
−
*[[Ivosidenib (AG-120)]]
 
  
 
[[Category:Acute myeloid leukemia regimens]]
 
[[Category:Acute myeloid leukemia regimens]]
 
[[Category:Biomarker-specific pages]]
 
[[Category:Biomarker-specific pages]]
 
[[Category:Acute leukemias]]
 
[[Category:Acute leukemias]]

Revision as of 22:24, 20 July 2018

Page editor
MartinSchoen.jpg
 Martin Schoen, MD, MPH
St. Louis, MO

Note: these are biomarker-specific regimens for patients with IDH-mutated AML, please see the main AML page for other regimens.

8 regimens on this page
8 variants on this page


IDH1 relapsed or refractory, salvage therapy

Ivosidenib monotherapy

back to top

Regimen

FDA-recommended dose
Study Evidence
DiNardo et al. 2018 (AG120-C-001) Phase I/II

Chemotherapy

Continued indefinitely

References

  1. AG120-C-001: DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018 Jun 21;378(25):2386-2398. Epub 2018 Jun 2. link to original article contains protocol PubMed

IDH2 Relapsed or refractory, salvage therapy

Enasidenib monotherapy

back to top

Regimen

FDA-recommended dose
Study Evidence Efficacy
Stein et al. 2017 (AG-221-C-001) Phase I/II ORR: 40%

This is the dose used in the phase II expansion cohort; enrolled patients were required to have IDH2-mutated advanced myeloid malignancies.

Chemotherapy

28-day cycles

References

  1. AG-221-C-001: Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Aug 10;130(6):722-731. Epub 2017 Jun 6. link to original article contains verified protocol link to PMC article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Acute_myeloid_leukemia,_IDH-mutated&oldid=28854"